Michael King Jolly
Senior Vice President, Strategic Development
Michael King Jolly joined Premier Research in 2016 to oversee strategic drug development partnerships and to implement innovative technologies and alliances. He has more than 33 years of clinical research and drug development experience, having held senior positions in strategic partnering, medical and regulatory affairs, clinical operations, and R&D at some of the industry’s leading companies.
Dr. Jolly came to Premier Research from Quintiles, where he founded and was Senior Vice President of the company’s Innovation business unit. Prior to that position, he served as Senior Vice President for Drug Development Partnerships at NovaQuest, the strategic partnering arm of Quintiles, and as the company’s Vice President for cardiovascular therapeutics.
“Premier Research is unique in that it has successfully built a business and customer engagement model that focuses on small biotechnology, virtual, and midsize pharma. No large CRO has built a successful business around this customer base.”
At King Pharmaceuticals, Dr. Jolly served as Executive Vice President for R&D, overseeing all clinical and preclinical research. He also was a Clinical Research Scientist and Associate Director at Burroughs Wellcome Company, where he began his pharmaceutical career.
He was drawn to Premier Research by its “transparent, collaborative, and progressive culture” and because its customers focus on “the most interesting science that is being done and the most challenging drug development problems being solved today.”
Dr. Jolly holds a Doctor of Pharmacy degree from the University of Texas-Austin and a bachelor’s degree in zoology from the University of North Carolina-Chapel Hill, and is a graduate of the Burroughs Wellcome Management Institute. He teaches at Duke University Medical School and the School of Pharmacy at the University of North Carolina-Chapel Hill.